GlassScriptPhysician profile
Wade B Bayless
NPI 1932795259
$2,079.11
in general payments reported to CMS, 2019-2025
15 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $31.03 · 2024: $763 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.07 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $605.41 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.68 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $104.20 | 2025 | Cobenfy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.01 | 2021 | |
| Tempus Ai, INC | $67.42 | 2024 | |
| Indivior INC. | $54.20 | 2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $34.83 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $30.47 | 2024 | |
| Novo Nordisk INC | $30.05 | 2021 | |
| Neurocrine Biosciences, INC. | $25.59 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $18.67 | 2025 | Trintellix |
| Lilly USA, LLC | $12.78 | 2021 | |
| Uswm, LLC | $12.11 | 2022 | |
| Eisai INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Bayless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.